PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29040827-1 2017 BACKGROUND: Accumulating evidence suggests that the FDA-approved serotonin 5-HT2C receptor agonist, lorcaserin (Belviq ), may be a promising candidate for the management of substance use disorders, including nicotine addiction. Nicotine 208-216 5-hydroxytryptamine receptor 2C Homo sapiens 65-90 23184281-8 2013 CONCLUSIONS: These studies support the utility of 5-HT2C agonists as a therapeutic approach to treat nicotine dependence. Nicotine 101-109 5-hydroxytryptamine receptor 2C Homo sapiens 50-56 24041919-4 2013 The availability of selective 5-HT2C agonists provides an opportunity to evaluate their potential as treatments for nicotine dependence or psychostimulant abuse, conditions for which there is significant medical need but only limited available treatment options. Nicotine 116-124 5-hydroxytryptamine receptor 2C Homo sapiens 30-36